Skip to main content
. 2021 Aug 26;12:668447. doi: 10.3389/fendo.2021.668447

Table 3.

Weighted national prevalence of GDM in pregnant women in 16 MENA countries by study period and overall.

Country/study period No. of studies Tested sample GDM GDM prevalence Heterogeneity measures p–value4 (fixed model)
Range (%) Median (%) Weighted prevalence % 95% CI Q (p–value)1 I2 (%)2 95% prediction interval (%)3
Algeria
 2010–2019 1 200 6 3.0 1.4–6.4
Bahrain <0.001 (<0.001)
 2000–2009 2 10,495 1,394 7.5–15.5 11.5 13.0 12.4–13.7
 2010–2019 9 49,552 4,982 6.9–13.3 9.5 9.7 8.1–11.6 352.4 (p<0.001) 97.7 4.2 – 17.2
 Overall 11 60,047 6,376 6.9–15.5 9.5 10.0 8.3–11.9 572.3 (p<0.001) 98.3 4.0–18.3
Egypt 0.21 (0.002)
 2010–2019 4 1,239 184 5.9–26.3 11.2 13.5 6.2–21.8 49.9 (p<0.001) 94.0 0.0–63.8
 Overlapping 2 308 24 7.6–7.9 7.8 7.8 5.0–11.1
 Overall 6 1,547 208 5.9–26.3 9.0 11.2 6.2–17.4 59.7 (p<0.001) 91.6 0.0–37.7
Iran 0.07 (<0.001)
 2000–2009 16 7,343 492 2.2–24.4 7.4 8.2 5.9–11.0 215.3 (p<0.001) 93.0 0.8–21.9
 2010–2019 39 21,028 2,235 0.0–50.0 9.2 12.3 9.0–16.0 2,135 (p<0.001) 98.2 0.0–41.0
 Overlapping 9 1,388 166 5.9–28.6 13.5 13.5 8.2–19.7 67.8 (p<0.001) 88.2 0.3–38.4
 Overall 64 29,759 2,893 0.0–50.0 8.8 11.4 9.2–13.9 2,491 (p<0.001) 97.5 0.1–35.8
Iraq
 2010–2019 4 383 35 2.6–24.5 14.2 11.5 3.3–23.3 24.5 (p<0.001) 87.8 0.0–76.6
Jordan
 2010–2019 6 43,847 604 1.2–31.7 4.7 4.7 3.0–6.7 193.7 (p<0.001) 97.4 0.4–12.5
Lebanon
 2010–2019 2 211 23 6.5–15.4 11.0 10.5 6.7–15.1
Libya
 Overlapping 1 28,140 405 1.4 1.3–1.6
Morocco
 2010–2019 2 1,880 393 13.3–18.3 15.8 15.5 13.9–17.2
Oman <0.001 (<0.001)
 2000–2009 2 1,345 44 2.9–4.4 3.7 3.2 2.3–4.2
 2010–2019 10 2,757 344 3.1–17.9 11.2 11 8.0–15.0 59.2 (p<0.001) 84.8 1.9–25.8
 Overlapping 2 147 24 9.9–26.8 18.3 15.5 10–21.9
 Overall 14 4,249 412 2.9–26.8 10.3 10.1 6.5–14.3 184.5 (p<0.001) 93.0 0.2–29.7
Qatar 0.65 (0.59)
 2000–2009 2 150 35 12.0–34.7 23.3 22.3 15.9–29.4
 2010–2019 17 21,513 4,772 2.4–47.0 22.5 20.5 14.8–26.9 1,869.0 (p<0.001) 99.1 1.6–52.6
 Overall 19 21,663 4,807 2.4–47.0 22.5 20.7 15.2–26.7 1,880.3 (p<0.001) 99.0 1.7–52.4
Saudi Arabia 0.02 (<0.001)
 2000–2009 16 17,499 1,286 0.0–50.7 7.2 10.8 6.2–16.5 1,330.5 (p<0.001) 98.9 0.0–41.1
 2010–2019 32 44,918 9,331 2.1–34.6 17.6 18.2 15.9–20.6 1,116.5 (p<0.001) 97.2 7.1–32.9
 Overall 48 62,417 10,617 0.0–50.7 16.1 15.5 12.6–18.8 4,989.3 (p<0.001) 99.1 1.0–41.9
Sudan
 2010–2019 3 411 94 12.0–46.2 15.1 23.0 3.3–45.2 47.2 (p<0.001) 95.8
Tunisia
 2010–2019 1 821 76 9.3 7.5–11.4
United Arab Emirates 0.3 (<0.001)
 2000–2009 7 18,738 3,402 7.1–30.7 13.4 15.5 9.2–23.0 736.7 (p<0.001) 99.2 0.2–46.9
 2010–2019 7 4,578 530 4.0–19.1 13.3 11.3 7.6–15.69 87.8 (p<0.001) 93.2 1.3–28.8
 Overall 14 23,316 3,932 4.0–30.7 13.3 13.4 9.4–18.0 945.1 (p<0.001) 98.6 1.1–35.6
Yemen
 2010–2019 2 311 16
Overall5 198 279,202 30,797 0.0–50.7 12.3 13.0 11.5–14.6 28,154 (p<0.001) 99.3 0.1–40.6

CI, confidence interval calculated using the exact binomial method; GDM, gestational diabetes mellitus; MENA, Middle East and North Africa.

1Q: Cochran’s Q statistic is a measure assessing the existence of heterogeneity in estimates of GDM prevalence.

2I2 is a measure assessing the percentage of between-study variation due to differences in GDM prevalence estimates across studies rather than chance.

3Prediction intervals estimate the 95% confidence interval in which the true GDM prevalence estimate in a new study is expected to fall.

4Heterogeneity between subgroups using random-effects model (fixed-effect model).

5Overall pooled estimates in the 16 countries regardless of the tested population, sample size, and data collection period, using the most updated criteria when GDM is ascertained using different criteria in the same population.